[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ursa Medicines\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100659274","phase-1-a-phase-1-study-of-vela-101-in-adult-participants-100659274",false,"NCT07864311","A Phase 1 Study of VELA-101 in Adult Participants","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VELA-101 in Adult Participants","Key Inclusion Criteria (All Parts):\n\n* Participants must be adults able to understand the study, provide written informed consent, and comply with study procedures.\n* Age: Part A: 18-55 years; Part B: 18-65 years\n* BMI and body weight: Part A: BMI 18.0-30.0 kg\u002Fm²; Part B: BMI 18.0-35.0 kg\u002Fm²\n* Considered medically healthy based on medical history and screening assessments.\n* Male and Female participants must agree to contraception requirements.\n\nKey Inclusion Criteria (Part B):\n\n\\- Elevated LDL-C and Lipoprotein(a)\n\nKey Exclusion Criteria (All Parts):\n\n* Known familial hypercholesterolemia or severe hypertriglyceridemia.\n* Clinically significant cardiovascular, liver, kidney, immune, or other medical disease.\n* Positive screening for HIV, hepatitis B, or hepatitis C.\n* Current significant infection, substance misuse, or other condition that could interfere with study participation.\n\nKey Exclusion Criteria (Part B):\n\n* Uncontrolled type 2 diabetes.\n* Recent changes in lipid-lowering therapy.\n* History of significant cardiovascular disease, including myocardial infarction, stroke, heart failure, significant arrhythmia, or uncontrolled hypertension.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses via subcutaneous (SC) administration.",[28,29],"Healthy Participants","Hyperlipidemia","NOT_YET_RECRUITING","2026-10-02",{"date":33,"type":34},"2026-10-07","ACTUAL",{"date":36,"type":22},"2026-11",{"date":38,"type":22},"2027-09",{"name":40,"class":41},"Ursa Medicines","INDUSTRY",2,""]